Park Avenue Securities LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,753 shares of the biopharmaceutical company's stock after buying an additional 6,878 shares during the quarter. Park Avenue Securities LLC's holdings in Gilead Sciences were worth $2,656,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of GILD. Kathmere Capital Management LLC boosted its stake in shares of Gilead Sciences by 42.7% during the 4th quarter. Kathmere Capital Management LLC now owns 17,527 shares of the biopharmaceutical company's stock worth $1,619,000 after acquiring an additional 5,246 shares in the last quarter. San Luis Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 3.3% in the fourth quarter. San Luis Wealth Advisors LLC now owns 9,885 shares of the biopharmaceutical company's stock valued at $913,000 after purchasing an additional 319 shares in the last quarter. Accurate Wealth Management LLC grew its position in shares of Gilead Sciences by 7.1% in the fourth quarter. Accurate Wealth Management LLC now owns 3,456 shares of the biopharmaceutical company's stock valued at $311,000 after purchasing an additional 230 shares during the last quarter. 180 Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 81.1% during the 4th quarter. 180 Wealth Advisors LLC now owns 10,990 shares of the biopharmaceutical company's stock worth $1,015,000 after purchasing an additional 4,920 shares in the last quarter. Finally, Global Financial Private Client LLC raised its position in shares of Gilead Sciences by 1,222.0% during the 4th quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock worth $561,000 after purchasing an additional 5,609 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
GILD has been the subject of several recent research reports. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Daiwa America upgraded Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Oppenheimer lifted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Finally, Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $97.96.
Get Our Latest Analysis on Gilead Sciences
Gilead Sciences Stock Up 0.2 %
NASDAQ GILD traded up $0.19 during trading hours on Friday, reaching $91.84. 6,852,085 shares of the company traded hands, compared to its average volume of 5,370,915. The company has a 50 day moving average of $91.75 and a two-hundred day moving average of $83.97. The stock has a market capitalization of $114.46 billion, a PE ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the firm earned $2.29 earnings per share. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio is presently 3,422.22%.
Insider Buying and Selling at Gilead Sciences
In other news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 over the last 90 days. Insiders own 0.29% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
